

## Roles of $\beta$ -Lactamases and Porins in Activities of Carbapenems and Cephalosporins against *Klebsiella pneumoniae*

LUIS MARTÍNEZ-MARTÍNEZ,<sup>1,2\*</sup> ALVARO PASCUAL,<sup>1,2</sup> SANTIAGO HERNÁNDEZ-ALLÉS,<sup>3</sup>  
DOLORES ALVAREZ-DÍAZ,<sup>3</sup> ANA ISABEL SUÁREZ,<sup>2</sup> JOHN TRAN,<sup>4</sup>  
VICENTE JAVIER BENEDÍ,<sup>3</sup> AND GEORGE A. JACOBY<sup>4</sup>

Department of Microbiology, School of Medicine, University of Seville,<sup>1</sup> and Department of Microbiology University Hospital V. Macarena,<sup>2</sup> Seville, and Area of Microbiology, Department of Biology and IMEDEA (CSIC-UIB), University of the Balearic Islands, Palma de Mallorca,<sup>3</sup> Spain, and Veterans Affairs Medical Center, Bedford and Lahey Clinic, Burlington, Massachusetts<sup>4</sup>

Received 9 September 1998/Returned for modification 19 January 1999/Accepted 30 April 1999

Two clinical isolates of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Klebsiella pneumoniae* were noted to be less susceptible than expected to imipenem. Both were missing outer membrane proteins that serve as channels for antibiotic entry. The role of  $\beta$ -lactamase in resistance was investigated by eliminating the original ESBL and introducing plasmids encoding various ESBLs and AmpC  $\beta$ -lactamase types, by studying the effect of an increased inoculum, and by evaluating interactions with  $\beta$ -lactamase inhibitors. The contribution of porin deficiency was investigated by restoring a functional *ompK36* gene on a plasmid. Plasmids encoding AmpC-type  $\beta$ -lactamases provided resistance to imipenem (up to 64  $\mu$ g/ml) and meropenem (up to 16  $\mu$ g/ml) in strains deficient in porins. Carbapenem resistance showed little inoculum effect, was not affected by clavulanate but was blocked by BRL 42715, and was diminished if *OmpK36* porin was restored. Plasmids encoding TEM- and SHV-type ESBLs conferred resistance to cefepime and ceftiprome, as well as to earlier oxymino- $\beta$ -lactams. This resistance was magnified with an increased inoculum, was blocked by clavulanate, and was also lowered by *OmpK36* porin restoration. In addition, SHV-2  $\beta$ -lactamase had a small effect on carbapenem resistance (imipenem MIC, 4  $\mu$ g/ml, increasing to 16  $\mu$ g/ml with a higher inoculum) when porins were absent. In *K. pneumoniae* porin loss can thus augment resistance provided either by TEM- or SHV-type ESBLs or by plasmid-mediated AmpC enzymes to include the latest oxymino- $\beta$ -lactams and carbapenems.

Carbapenems are usually active against extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Klebsiella pneumoniae* strains, including porin-deficient ones (13). The MICs of meropenem for clinical isolates of *K. pneumoniae* strains that produce ESBLs are usually 8 to 16 lower than the MICs of imipenem (4, 27). Carbapenems are also usually active against plasmid-mediated AmpC-type  $\beta$ -lactamase-producing strains (10, 16). Imipenem-resistant *K. pneumoniae* strains that produce ACT-1 (an AmpC-type  $\beta$ -lactamase) (3) or ESBL SHV-2 (18) and that are deficient in a major outer membrane protein, presumably a porin, have been reported recently.

Plasmid- or chromosome-encoded carbapenemases (17) or the association of reduced outer membrane permeability with increased chromosomal  $\beta$ -lactamase production have been shown to be the major mechanisms of resistance to carbapenems in several species of enterobacteria, including *Enterobacter* spp. (5, 7, 9, 29), *Serratia marcescens* (25, 36), *Citrobacter freundii* (19), *Providencia rettgeri* (29), and *Escherichia coli* (6, 28). The association of porin loss and metallo- $\beta$ -lactamase production in laboratory-constructed strains of *E. coli* determined resistance to both imipenem and meropenem when a high bacterial inoculum was used (6).

As a part of a study of resistance to expanded-spectrum  $\beta$ -lactams in enterobacteria, two clinical isolates of *K. pneumoniae* that were resistant to ceftazidime (MICs, >256  $\mu$ g/ml for both strains) and that presented with reduced sensitivity to imipenem (MICs, 2  $\mu$ g/ml) have been identified. The objec-

tives of this work were to evaluate the mechanisms for the increased MIC of imipenem for these two clinical isolates and to evaluate the relative roles of porins and  $\beta$ -lactamases (both plasmid-mediated ESBLs and plasmid-mediated AmpC-type enzymes) in the activities of imipenem, meropenem, and cephalosporins against *K. pneumoniae*.

(This study was presented in part in the 36th and 37th Interscience Conferences on Antimicrobial Agents and Chemotherapy, New Orleans, La. [20a], 15 to 18 September 1996 and Toronto, Ontario, Canada, 28 September to 1 October 1997 [21a], respectively.)

### MATERIALS AND METHODS

**Bacterial strains.** *K. pneumoniae* 143098-3 was cultured from sputum at the Massachusetts General Hospital, Boston, in December 1993. It was resistant to ceftazidime, cefotaxime, aztreonam, cefotetan, cefoxitin, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, sulfonamide, tetracycline, tobramycin, and trimethoprim and had a 16-mm zone diameter around a 10- $\mu$ g imipenem disk. On isoelectric focusing (22) *K. pneumoniae* 143098-3 had  $\beta$ -lactamase bands at pIs 5.4, 7.6, and 8.2, consistent with TEM-1, SHV-1, and SHV-5 respectively, and could transfer a plasmid (designated pMG257) encoding the pI 5.4 and 8.2  $\beta$ -lactamases to *E. coli* J53 Rif<sup>r</sup> by selection with ceftazidime. Strain C1 was obtained from strain 143098-3 after overnight growth at 43°C by replica plating for a ceftazidime susceptible derivative. It was also cefotaxime and aztreonam sensitive but retained the parent's resistance to the other drugs except that the imipenem disk diameter was 24 mm. On isoelectric focusing,  $\beta$ -lactamase bands at pIs 5.4 and 7.6 were retained, but the band at pI 8.2 was no longer present, suggesting that the putative SHV-5 enzyme was no longer expressed. Attempts to cure the entire resistance phenotype with acridine orange, ethidium bromide, novobiocin, or sodium dodecyl sulfate (SDS) were unsuccessful.

*K. pneumoniae* NEDH-1 is a urine isolate obtained at the New England Deaconess Hospital, Boston, Mass., in August 1994. The isolate was resistant to ceftazidime, cefotaxime, aztreonam, chloramphenicol, kanamycin, streptomycin, sulfonamide, tobramycin, and trimethoprim and could transfer a plasmid (named pMG258) encoding resistance to these drugs on mating to *E. coli*. On isoelectric focusing,  $\beta$ -lactamase bands at pIs 5.4 and 7.6 consistent with TEM-1 and

\* Corresponding author. Mailing address: Department of Microbiology, School of Medicine, University of Seville, Apdo. 914, 41080 Seville, Spain. Phone: 34-95-4557448. Fax: 34-95-4377413. E-mail: lmartin@cica.es.

TABLE 1. Plasmids used in the study

Plasmid	Enzyme	Origin	Reference
pMG226	TEM-6	Munich, Germany	2, 11
pMG223	TEM-10	Boston, Mass.	11, 31
pMG224	TEM-12	Cambridge, Mass.	30, 31
pMG225	TEM-26	Cambridge, Mass.	30, 31
pMG229	SHV-2	Paris, France	11, 13
pMG258	SHV-2 <sup>a</sup>	Boston, Mass.	This paper
pDU18	SHV-3	Paris, France	24
pMG257	SHV-5 <sup>a</sup>	Boston, Mass.	This paper
pMG233	AmpC <sup>b</sup>	Providence, R.I.	26
pMG245	AmpC <sup>b</sup>	Boston, Mass.	12
pMG248	AmpC <sup>c</sup>	Durham, N.C.	12
pMG250	AmpC <sup>d</sup>	Ann Arbor, Mich.	12
pMG252	AmpC <sup>e</sup>	Birmingham, Ala.	21

<sup>a</sup> Presumptive identification based on pI determination.

<sup>b</sup> *Enterobacter cloacae* type.

<sup>c</sup> Sequence not yet analyzed.

<sup>d</sup> *C. freundii* type.

<sup>e</sup> Related to the group of AmpC-type  $\beta$ -lactamases distantly related to the chromosomal enzyme of *P. aeruginosa*.

SHV-2, respectively, were present. C2 was derived from strain NEDH-1 by growth in ethidium bromide and screening for a ceftazidime-susceptible derivative. It lost the resistance of the parent to all drugs listed above and no longer produced  $\beta$ -lactamase, suggesting that pMG258 had been completely eliminated.

Plasmids coding for different TEM- or SHV-type ESBLs or AmpC-type enzymes were introduced by conjugation, as described previously (14), into C1 and C2 (Table 1).

The role of porin *OmpK36* expression in the resistance of  $\beta$ -lactamase-producing strains was tested by transformation with plasmid pSHA2, which encodes the *OmpK36* porin and which contains a potassium tellurite resistance cassette (for selection purposes) (20). Plasmid pSHA4 (which also codes for resistance to tellurite and which is equivalent to pSHA2 but which has a truncated *ompK36* gene) was used as a control. Transformants were obtained on Mueller-Hinton agar containing ceftazidime (20  $\mu$ g/ml) and potassium tellurite (30  $\mu$ g/ml).

*E. coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality control strains for susceptibility testing.

**Susceptibility testing.** The following antimicrobial agents were tested: ceftazidime (Sigma, Madrid, Spain), ceftazidime (Sigma), cefepime (Bristol-Myers Squibb, Madrid, Spain), ceftiofime (Hoescht Marion-Roussel, Romainville, France), imipenem (Merck Sharpe & Dohme, Madrid, Spain), meropenem (Zeneca Farma, Madrid, Spain), and ciprofloxacin (Sigma). All  $\beta$ -lactams were tested alone or in combination with a fixed concentration (2  $\mu$ g/ml) of clavulanic acid (SmithKline Beecham, Madrid, Spain), a well-known ESBL inhibitor. The combinations of ceftiofime, imipenem, and meropenem with the serine- $\beta$ -lactamase inhibitor BRL 42715 (SmithKline Beecham) were also tested against strains that express AmpC-type enzymes. BRL 42715 is able to inhibit not only class A  $\beta$ -lactamases but also class C enzymes, and for this reason it was expected that it would inhibit the plasmid-mediated AmpC-type enzymes evaluated in the present study. MICs were determined in cation-adjusted Mueller-Hinton broth, according to the guidelines of the National Committee for Clinical Laboratory Standards (23). The activities of ceftiofime, ceftiofime, imipenem, and meropenem were compared at inocula of  $10^5$  and  $10^7$  CFU/ml. The E test was also used for some assays. Media were supplemented with potassium tellurite (30  $\mu$ g/ml) when strains carrying pSHA plasmids were studied in order to avoid plasmid loss.

**Isoelectric focusing of  $\beta$ -lactamases.** Cells were grown to the logarithmic phase and were disrupted by sonication. After removal of nonbroken cells and debris, the supernatant was used to determine pIs by isoelectric focusing as described previously (20, 22).  $\beta$ -Lactamases with known pIs (TEM-1, pI 5.4; TEM-3, pI 6.3; TEM-4, pI 5.9; TEM-26, pI 5.6; SHV-3, pI 7.0; SHV-2, pI 7.6; and SHV-5, pI 8.2) were used for comparison.

**Isolation and analysis of OMPs.** Outer membrane proteins (OMPs) were isolated as sodium lauryl sarcosinate (2%)-insoluble material from cell envelopes obtained by sonication of bacteria grown in nutrient broth (8). Electrophoretic analysis of OMPs was performed by SDS-polyacrylamide gel electrophoresis (PAGE) as described elsewhere (15, 20).

**DNA manipulations.** Plasmids pSHA2 and pSHA4 were transformed into the desired strains by electroporation. Standard procedures for agarose gel electrophoresis and plasmid transformation were used (32).

## RESULTS

*K. pneumoniae* C1 and C2 were deficient in both *OmpK35* and *OmpK36* porins, as determined by SDS-PAGE (data not shown). Tables 2 and 3 show that introduction of TEM- or SHV-type ESBLs into these strains increased the MICs of

TABLE 2. MICs of antimicrobial agents determined by microdilution for ESBL- or AmpC-producing strains of *K. pneumoniae* at an inoculum of  $10^5$  or  $10^7$  CFU/ml

Strain	Plasmid	Enzyme	MIC ( $\mu$ g/ml) at the indicated inoculum (CFU/ml) <sup>a</sup> :									
			FOX, $10^5$	FEP		PIR		IPM		MEM		CIP, $10^5$
				$10^5$	$10^7$	$10^5$	$10^7$	$10^5$	$10^7$	$10^5$	$10^7$	
143098-3 <sup>b</sup>	pMG257	SHV-5	64	128	>256	128	>256	2	2	2	2	8
C1	No ESBL		128	1	2	0.5	2	1	1	1	1	8
C1-T6	pMG226	TEM-6	128	32	>256	64	>256	1	2	1	2	8
C1-T10	pMG223	TEM-10	64	8	>256	32	>256	1	4	2	1	8
C1-T12	pMG224	TEM-12	128	64	>256	128	>256	1	1	1	1	8
C1-T26	pMG225	TEM-26	128	16	>256	32	>256	1	2	1	2	8
C1-S2	pMG229	SHV-2	128	>256	>256	256	>256	4	16	4	4	8
C1-S3	pUD18	SHV-3	128	16	>256	16	>256	2	2	2	2	4
C1-S5	pMG257	SHV-5 <sup>c</sup>	64	128	>256	128	>256	2	2	2	2	8
C1-AC233	pMG233	AmpC	>256	1	>256	4	8	64	64	16	16	8
C1-AC245	pMG245	AmpC	>256	1	>256	4	32	32	64	16	16	4
C1-AC248	pMG248	AmpC	>256	2	>256	8	>256	32	64	4	16	8
C1-AC252	pMG252	AmpC	>256	2	32	16	>256	1	2	2	4	32
NEDH-1 <sup>d</sup>	pMG258	SHV-2	64	>256	>256	>256	>256	2	2	2	2	0.5
C2	No ESBL		64	0.25	$\leq 0.5$	0.5	0.5	1	2	0.25	1	0.5
C2-S2	pMG258	SHV-2 <sup>c</sup>	64	>256	>256	>256	>256	2	2	1	2	0.5
C2-AC248	pMG248	AmpC	>256	8	32	64	128	64	64	16	16	0.5
C2-AC250	pMG250	AmpC	>256	2	16	16	32	16	32	4	8	0.5
C2-AC252	pMG252	AmpC	>256	4	>32	32	>32	0.5	2	0.5	2	4

<sup>a</sup> Abbreviations: FOX, ceftiofime; IPM, imipenem; MEM, meropenem; FEP, cefepime; PIR, ceftiofime; CIP, ciprofloxacin.

<sup>b</sup> Parental strain of strain C1.

<sup>c</sup> Presumptive identification based on pI.

<sup>d</sup> Parental strain of strain C2.

TABLE 3. MICs of cephalosporins and carbapenems alone and combined with clavulanic acid or BRL 42715 for *K. pneumoniae* strains producing different  $\beta$ -lactamases

Strain	Enzyme	MIC ( $\mu\text{g/ml}$ ) with the indicated inhibitor <sup>a</sup> :														
		CAZ		FEP		PIR		FOX			IMP			MEM		
		NI	CLA	NI	CLA	NI	CLA	NI	CLA	BRL	NI	CLA	BRL	NI	CLA	BRL
143098-3	SHV-5 <sup>b</sup>	>256	$\leq 0.5$	128	ND	128	ND	64	64	64	2	1	1	2	2	2
C1	No ESBL	2	$\leq 0.5$	1	1	$\leq 0.5$	1	128	64	64	1	0.5	0.5	1	1	2
C1-T6	TEM-6	>256	$\leq 0.5$	32	1	64	1	128	64	ND	1	1	ND	1	1	ND
C1-T10	TEM-10	128	1	8	2	32	4	64	64	ND	1	0.5	ND	2	1	ND
C1-T12	TEM-12	>256	8	64	1	128	2	128	128	ND	1	1	ND	1	1	ND
C1-T26	TEM-26	>256	$\leq 0.5$	16	1	32	2	128	128	ND	1	1	ND	1	1	ND
C1-S2	SHV-2	>256	$\leq 0.5$	>256	16	256	16	128	128	ND	4	4	ND	4	4	ND
C1-S3	SHV-3	>256	8	16	2	16	2	128	64	ND	2	1	ND	2	1	ND
C1-S5	SHV-5	>256	$\leq 0.5$	128	2	128	4	64	64	64	2	1	1	2	2	2
C1-AC233	AmpC	64	64	1	0.5	4	2	>1,024	>1,024	64	64	32	1	16	8	2
C1-AC245	AmpC	128	128	1	0.5	4	2	>1,024	>1,024	64	64	32	4	16	8	2
C1-AC248	AmpC	128	64	2	1	8	4	>1,024	>1,024	128	32	16	2	4	4	2
C1-AC252	AmpC	256	128	2	1	16	8	>1,024	>1,024	64	1	1	0.5	2	4	2
NEDH-1	SHV-2	>256	2	>256	ND	>256	ND	64	64	64	2	0.5	1	2	2	1
C2	Cured	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	64	32	32	1	0.5	0.5	0.25	0.5	0.5
C2-S2	SHV-2	>256	4	>256	$\leq 0.5$	>256	2	64	32	ND	2	1	ND	1	0.5	ND

<sup>a</sup> Abbreviations: CAZ, ceftazidime; PIM, cefepime; PIR, ceftipime; FOX, ceftoxitin; IMP, imipenem; MEM, meropenem; CLA, clavulanic acid; BRL, BRL 42715; NI, no inhibitor; ND, not determined.

<sup>b</sup> Presumptive identification based on pI determination.

ceftazidime, cefepime, and ceftipime but not that of ceftoxitin. The MICs of imipenem and meropenem were not increased except for a fourfold increase with the SHV-2  $\beta$ -lactamase. Introduction of plasmids encoding AmpC-type  $\beta$ -lactamases also increased the MICs of cefepime and ceftipime, but to a lesser extent, especially for cefepime. Cefoxitin MICs were higher by acquisition of AmpC-type enzymes, and all except the enzyme determined by pMG252 increased imipenem MICs as much as 64-fold and meropenem MICs up to 16-fold.

Table 2 shows that increasing the test inoculum from  $10^5$  to  $10^7$  CFU/ml resulted in higher MICs of cefepime and ceftipime for both ESBL- and AmpC-producing strains. The higher inoculum did not enhance the carbapenem resistance of the ESBL-producing strains except for those with SHV-2, for which the imipenem MIC reached 16  $\mu\text{g/ml}$ . With AmpC strains carbapenem resistance showed a two- to fourfold inoculum effect, with MICs of 64  $\mu\text{g/ml}$  for imipenem and 16  $\mu\text{g/ml}$  for meropenem.

Clavulanic acid blocked resistance to ceftazidime, cefepime,

and ceftipime produced by TEM- and SHV-type ESBLs in strains C1 and C2 (Table 3). The resistance to ceftoxitin, imipenem, and meropenem produced by AmpC-type  $\beta$ -lactamases was reduced by BRL 42715 but not by clavulanic acid (Table 3).

SDS-PAGE analysis documented that the missing OmpK36 porin was restored by transformation with plasmid pSHA2. Control strains transformed with plasmid pSHA4 (which encodes a truncated *ompK36* gene) remained OmpK36 deficient (data not shown). Table 4 shows that restoration of OmpK36 lowered the MICs of ceftazidime, ceftoxitin, cefepime, and ceftipime and, for AmpC-producing strains, the MICs of imipenem and meropenem. The MICs of imipenem (32 to 64  $\mu\text{g/ml}$ ) and meropenem (16  $\mu\text{g/ml}$ ) were reduced to 0.5 to 2 and 0.25  $\mu\text{g/ml}$ , respectively, by a functional OmpK36 porin. The MICs of ceftoxitin, imipenem, and meropenem in the presence of BRL 42715 for strain C1-AC248 that expressed or that did not express porin OmpK36 were 4 and 128  $\mu\text{g/ml}$ , respectively, for ceftoxitin, 1 and 1  $\mu\text{g/ml}$ , respectively, for imipenem,

TABLE 4. MICs of antimicrobial agents for *K. pneumoniae* strains that produce different ESBLs and that express or do not express OmpK36 porin

Strain	Enzyme	MIC ( $\mu\text{g/ml}$ ) <sup>a</sup>											
		FOX		CAZ		FEP		PIR		IPM		MEM	
		OmpK36 (+)	OmpK36 (-)	OmpK36 (+)	OmpK36 (-)	OmpK36 (+)	OmpK36 (-)	OmpK36 (+)	OmpK36 (-)	OmpK36 (+)	OmpK36 (-)	OmpK36 (+)	OmpK36 (-)
C1	No ESBL	4	>256	1	3	0.125	0.5	0.094	0.125	1.5	1.5	ND	ND
C1-T6	TEM-6	8	>256	32	>256	4	32	3	64	1.5	1.5	ND	ND
C1-T12	TEM-12	12	>256	>256	>256	4	64	0.5	64	1	1	ND	ND
C1-T26	TEM-26	8	>256	>256	>256	1.5	8	1	16	1	1	ND	ND
C1-S2	SHV-2	16	>256	>256	>256	6	>256	4	64	3	4	ND	ND
C1-S3	SHV-3	4	192	>256	>256	0.5	16	0.75	32	1.5	2	ND	ND
C1-S5	SHV-5	8	96	>256	>256	3	64	1	64	2	2	ND	ND
C1-AC248	AmpC	64	>256	64	128	0.25	1	1	4	2	32	0.25	16
C2-AC248	AmpC	128	>256	256	>256	1	4	2	16	0.5	64	0.25	16

<sup>a</sup> MICs were determined with E-test strips. OmpK36(+), OmpK36 porin expression; OmpK36(-), OmpK36 porin nonexpression; ND, not determined. Antibiotic abbreviations are as in footnotes a of Tables 2 and 3.

and 0.25 and 4  $\mu\text{g/ml}$ , respectively, for meropenem. The corresponding values for strain C2-AC248 that expressed or that did not express OmpK36 were 4 and 64  $\mu\text{g/ml}$ , respectively, for cefoxitin, 0.125 and 0.25  $\mu\text{g/ml}$ , respectively, for imipenem, and 0.03 and 0.25  $\mu\text{g/ml}$ , respectively, for meropenem.

## DISCUSSION

Results from this study confirm previous observations (20, 35) indicating that resistance to expanded-spectrum cephalosporins increases in *K. pneumoniae* strains that produce TEM- or SHV-type ESBLs that lack the two major porins of the species (OmpK35 and OmpK36). The level of resistance further increased when a high inoculum ( $10^7$  CFU/ml) was used, and this may be clinically relevant in situations in which the number of bacteria at the site of infection is particularly high.

Restoration of OmpK36 function in porin-deficient strains producing ESBLs caused significant decreases in the MICs of ceftazidime, cefepime, and ceftiprome. In *E. coli* we have observed that the expression of OmpF in strains that are deficient in both OmpF and OmpC porins and that hyperproduce chromosomal  $\beta$ -lactamase is more efficient than expression of OmpC in reverting the resistant phenotype (28). It has been previously shown that the OmpK36 porin of *K. pneumoniae* is homologous to OmpC of *E. coli* (1). Cloning of the *ompK35* gene of *K. pneumoniae* is in progress and will allow evaluation of the role of this other porin, in comparison with that of OmpK36, in the resistance of *K. pneumoniae* to antimicrobial agents.

ESBL production did not affect the activities of carbapenems except when imipenem was tested against strain C1-S2 (which produces SHV-2), for which MICs of 4  $\mu\text{g/ml}$  ( $10^5$  cfu/ml) and 16  $\mu\text{g/ml}$  ( $10^7$  cfu/ml) were obtained. It has previously been reported that a clinical isolate of *K. pneumoniae* that produces SHV-2 was resistant to imipenem (MIC, 8  $\mu\text{g/ml}$ ) and meropenem (MIC, 16  $\mu\text{g/ml}$ ) (18).

The expression of AmpC-type enzymes affected the activities of cefoxitin (which is in contrast to the effects of ESBLs) and ceftazidime, as has been shown for other plasmid-mediated AmpC-type  $\beta$ -lactamases (10, 16). On the other hand, only moderate increases were observed when cefepime or ceftiprome were tested, with cefepime MICs being two to eight times lower than those of ceftiprome. The relative better activities of both cefepime and ceftiprome in comparison with those of older cephalosporin derivatives relates to their increased stability to chromosomal AmpC enzymes (from which plasmid-mediated AmpC-type enzymes have been shown to be derived) and to their relatively higher level of permeation through the outer membranes of gram-negative bacteria (33). These data suggest that cefepime and ceftiprome could represent therapeutic alternatives against AmpC-type producing organisms resistant to multiple antimicrobial agents, as has already been shown for infections caused by ceftazidime-resistant *Enterobacter* (34). Caution is suggested, however, from the significant increases in the MICs of both cefepime and ceftiprome when a high inoculum was used in the susceptibility assay.

The production of AmpC-type enzymes significantly increased the MICs of carbapenems, in agreement with the report by Bradford et al. (3) with the ACT-1  $\beta$ -lactamase. BRL 42715 was able to revert the resistance conferred by AmpC-type enzymes, as expected for class C-related  $\beta$ -lactamases (16). Although BRL 42715 is not available for clinical use, it would be interesting to develop compounds with activity similar to that of BRL 42715 to assess their therapeutic potential. Resistance to carbapenems also depends on the absence of porins, because restoration of OmpK36 significantly reduced

the level of resistance. The results obtained after simultaneous inhibition of the AmpC enzyme and expression of OmpK36 in strains C1-AC248 and C2-AC248 suggest that  $\beta$ -lactamase production is the most important factor for resistance to imipenem, while loss of porins seems more important or as important for resistance to meropenem.

The apparent existence of different mechanisms of resistance to imipenem and meropenem in *K. pneumoniae* is also supported by the observation that inhibition of the AmpC enzymes of strains C1-AC248 and C2-AC248 with the same amount of BRL 42715 resulted in a larger decrease in the MICs of imipenem for C2-AC248 than for C1-AC248. Similarly, although both strains present similar levels of resistance to meropenem, the decrease in the MIC of this agent in the presence of BRL 42715 was also higher for strain C2-AC248. It is unlikely that this was caused by a poorer inhibition of the enzyme in strain C1-AC248, because an increase in the concentration of BRL 42715 to 16  $\mu\text{g/ml}$  did not result in an additional decrease in the MIC of either imipenem or meropenem (data not shown).

Although the main objective of this study was to evaluate the mechanisms that lead to resistance to carbapenems and cephalosporins in *K. pneumoniae*, ciprofloxacin was also included as a control for experiments on OmpK36 expression, because its activity is slightly increased when this porin is produced (20) and possible interactions between  $\beta$ -lactamase expression and fluoroquinolone activity were of interest. Surprisingly, one of the plasmids coding for an AmpC-type enzyme (pMG252) was able to increase the resistance to ciprofloxacin in the two *K. pneumoniae* strains evaluated. Details about this finding have been published elsewhere (21). It is noteworthy that pMG252 was the only plasmid of those evaluated in the present study that codes for an enzyme that determined resistance to cefoxitin but not to carbapenems. The AmpC-type enzyme encoded by this plasmid belongs to the group of plasmid-mediated AmpC-type  $\beta$ -lactamases (CMY-1, FOX-1, MOX-1, and others) distantly related to the chromosomal enzyme of *P. aeruginosa* (unpublished data). More enzymes of this type need to be tested to determine if this is a general and potentially distinguishing property of this class of enzymes.

Plasmid-mediated AmpC-type enzymes have increasingly been recognized in recent years. Data from previous reports and from this work suggest that these bacterial enzymes may represent a new threat against the more recently introduced antimicrobial agents. The spread of strains that lack porins and that express these new plasmid-mediated enzymes may create serious therapeutic problems in the future.

## ACKNOWLEDGMENTS

This study was supported by grants from Consolidation of Research Groups, Consejería de Educación, Junta de Andalucía (to L.M.-M. and A.P.), and from the Comisión Interministerial de Ciencia y Tecnología, Ministerio de Educación (grant PB96-0197) (to V.J.B.). G.A.J. was partially supported by a VA/DoD Mechanisms of Emerging Pathogens award.

## REFERENCES

- Albertí, S., F. Rodríguez-Quiñones, T. Schirmer, G. Rummel, J. M. Tomás, J. P. Rosenbusch, and V. J. Benedí. 1995. A porin from *Klebsiella pneumoniae*: sequence homology, three-dimensional structure, and complement binding. *Infect. Immun.* **63**:903–910.
- Bauernfeind, A., and G. Hörl. 1987. Novel R-factor borne  $\beta$ -lactamase of *Escherichia coli* conferring resistance to cephalosporins. *Infection* **15**:257–259.
- Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K. Bush. 1997. Imipenem resistance in *Klebsiella pneumoniae* is associated with the combination of ACT-1, a plasmid-mediated AmpC  $\beta$ -lactamase, and the loss of an outer membrane protein. *Antimicrob. Agents Chemother.* **41**:563–569.

4. Chanal, C., D. Sirot, M. Chanal, M. Cluzel, J. Sirot, and R. Cluzel. 1989. Comparative in-vitro activity of meropenem against clinical isolates including *Enterobacteriaceae* with expanded-spectrum  $\beta$ -lactamases. *J. Antimicrob. Chemother.* **24**(Suppl. A):133–141.
5. Chow, J. W., and D. M. Shlaes. 1991. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in *Enterobacter aerogenes*. *J. Antimicrob. Chemother.* **28**:499–504.
6. Cornaglia, G., L. Guang, R. Fontana, and G. Satta. 1992. Diffusion of meropenem and imipenem through the outer membrane of *Escherichia coli* K-12 and correlation with their antibacterial activities. *Antimicrob. Agents Chemother.* **36**:1902–1908.
7. Cornaglia, G., K. Russel, G. Satta, and R. Fontana. 1995. Relative importance of outer membrane permeability and group 1  $\beta$ -lactamase as determinants of meropenem and imipenem activities against *Enterobacter cloacae*. *Antimicrob. Agents Chemother.* **39**:350–355.
8. Filip, C., G. Fletcher, J. L. Wulf, and C. F. Earhart. 1973. Solubilization of the cytoplasmic membrane of *Escherichia coli* by the ionic detergent sodium-lauryl sarcosinate. *J. Bacteriol.* **115**:717–722.
9. Hopkins, J. M., and K. J. Towner. 1990. Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in *Enterobacter aerogenes*. *J. Antimicrob. Chemother.* **25**:49–55.
10. Jacoby, G. A. 1994. Genetics of extended-spectrum beta-lactamases. *Eur. J. Clin. Microbiol. Infect. Dis.* **13**(Suppl. 1):2–11.
11. Jacoby, G. A., and L. Sutton. 1991. Properties of plasmids responsible for extended-spectrum  $\beta$ -lactamase production. *Antimicrob. Agents Chemother.* **35**:164–169.
12. Jacoby, G. A., P. Han, M. Alvarez, and F. Tenover. 1995. Survey of extended-spectrum  $\beta$ -lactamase (ESBL) production in US clinical isolates, abstr. C40, p. 46. *In* Program and abstracts of the 35th Interscience Conference Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Jarlier, V., M.-H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum  $\beta$ -lactamases conferring transferable resistance to newer  $\beta$ -lactam agents in *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* **10**:867–878.
14. Katsanis, G. P., J. Spargo, M. J. Ferraro, L. Sutton, and G. A. Jacoby. 1994. Detection of *Klebsiella pneumoniae* and *Escherichia coli* strains producing extended-spectrum  $\beta$ -lactamases. *Antimicrob. Agents Chemother.* **32**:691–696.
15. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (London)* **227**:680–685.
16. Livermore, D. M. 1995.  $\beta$ -Lactamases in clinical and laboratory resistance. *Clin. Microbiol. Rev.* **8**:557–584.
17. Livermore, D. M. 1997. Acquired carbapenemases. *J. Antimicrob. Chemother.* **39**:673–676.
18. Mackenzie, F. M., K. J. Forbes, T. Dorai-john, S. G. B. Amyes, and I. M. Gould. 1997. Emergence of a carbapenem-resistant *Klebsiella pneumoniae*. *Lancet* **350**:783.
19. Mainardi, J.-L., P. Mugnier, A. Coutrot, A. Buu-Hoi, E. Collatz, and L. Gutmann. 1997. Carbapenem resistance in a clinical isolate of *Citrobacter freundii*. *Antimicrob. Agents Chemother.* **41**:2352–2354.
20. Martínez-Martínez, L., S. Hernández-Allés, S. Albertí, J. M. Tomás, V. J. Benedí, and G. A. Jacoby. 1996. In vivo selection of porin-deficient mutants of *Klebsiella pneumoniae* with increased resistance to cefoxitin and expanded-spectrum cephalosporins. *Antimicrob. Agents Chemother.* **40**:342–348.
- 20a. Martínez-Martínez, L., A. Pascual, S. Hernández-Allés, D. Alvarez-Díaz, V. J. Benedí, and G. A. Jacoby. 1996. Role of extended-spectrum beta-lactamases (ESBLs) and OmpK36 porin in the activity of antimicrobial agents against *Klebsiella pneumoniae*, abstr. C37, p. 41. *In* Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Martínez-Martínez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. *Lancet* **351**:797–799.
- 21a. Martínez-Martínez, L., A. Pascual, A. I. Suárez, S. Hernández-Allés, D. Alvarez-Díaz, and V. J. Benedí. 1997. Resistance to carbapenems in porin-deficient *Klebsiella pneumoniae* (Kp) mediated by plasma-encoded AmpC beta-lactamases, abstr. C-94, p. 62. *In* Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of  $\beta$ -lactamases. *J. Gen. Microbiol.* **88**:169–178.
23. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Nicolas, M.-H., V. Jarlier, N. Honore, A. Philippon, and S. T. Cole. 1989. Molecular characterization of the gene encoding SHV-3  $\beta$ -lactamase responsible for transferable cefotaxime resistance in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **33**:2096–2100.
25. Osano, E., Y. Arakawa, R. Wacharatyankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura, and N. Kato. 1994. Molecular characterization of an enterobacterial metallo- $\beta$ -lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. *Antimicrob. Agents Chemother.* **38**:71–78.
26. Papanicolaou, G. A., A. A. Medeiros, and G. A. Jacoby. 1990. Novel plasmid-mediated  $\beta$ -lactamase (MIR-1) conferring resistance to oxyimino- and  $\alpha$ -methoxy  $\beta$ -lactams in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **34**:2200–2209.
27. Piddock, L. V. J., and H. L. Turner. 1992. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant *Enterobacteriaceae*. *Eur. J. Clin. Microbiol. Infect. Dis.* **11**:1186–1191.
28. Prágai, Z., S. Hernández-Allés, M. C. Conejo, M. D. Alvarez, V. J. Benedí, and L. Martínez-Martínez. 1998. Effect of OmpF/OmpC expression in the activity of cephalosporins and carbapenems against *Escherichia coli* hyper-producing chromosomal beta-lactamases, abstr. 12009, p. 15. *In* Program and abstracts of the 8th International Congress of Infectious Diseases. Excerpta Medical Communications, Boston, Mass.
29. Raimondi, A., A. Traverso, and H. Nikaido. 1991. Imipenem- and meropenem-resistant mutants of *Enterobacter cloacae* and *Proteus rettgeri* lack porins. *Antimicrob. Agents Chemother.* **35**:1174–1180.
30. Rice, L. B., S. H. Marshall, L. L. Carias, L. Sutton, and G. A. Jacoby. 1993. Sequences of MGH-1, YOU-1, and YOU-2 extended-spectrum  $\beta$ -lactamase genes. *Antimicrob. Agents Chemother.* **37**:2760–2761.
31. Rice, L. B., S. H. Willey, G. A. Papanicolaou, A. A. Medeiros, G. M. Eliopoulos, R. C. Moeller, Jr., and G. A. Jacoby. 1990. Outbreak of ceftazidime resistance caused by extended-spectrum  $\beta$ -lactamases at a Massachusetts chronic-care facility. *Antimicrob. Agents Chemother.* **34**:2193–2199.
32. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
33. Sanders, C. C. 1996. In vitro activity of fourth generation cephalosporins against *Enterobacteriaceae* producing extended-spectrum  $\beta$ -lactamases. *J. Chemother.* **8**(Suppl. 2):57–62.
34. Sanders, W. E., J. H. Tenney, and R. E. Kessler. 1996. Efficacy of cefepime in the treatment of infections due to multiply resistant *Enterobacter* species. *Clin. Infect. Dis.* **23**:454–461.
35. Tzouveleki, L. S., E. Tzelepi, E. Prinarakis, M. Gazouli, A. Katrahouria, P. Giakkoupi, O. Paniara, and N. J. Legakis. 1998. Sporadic emergence of *Klebsiella pneumoniae* strains resistant to cefepime and ceftipime in greek hospitals. *J. Clin. Microbiol.* **36**:266–268.
36. Yang, Y., P. Wu, and D. M. Livermore. 1990. Biochemical characterization of a  $\beta$ -lactamase that hydrolyzes penems and carbapenems from two *Serratia marcescens* isolates. *Antimicrob. Agents Chemother.* **34**:755–758.